KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Consolidated Net Income: 2013-2025

Historic Consolidated Net Income for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to -$90.9 million.

  • Xenon Pharmaceuticals' Consolidated Net Income fell 44.76% to -$90.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$320.2 million, marking a year-over-year decrease of 50.05%. This contributed to the annual value of -$248.2 million for FY2024, which is 36.07% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Consolidated Net Income of -$90.9 million as of Q3 2025, which was down 7.31% from -$84.7 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Consolidated Net Income ranged from a high of -$15.4 million in Q3 2021 and a low of -$90.9 million during Q3 2025.
  • For the 3-year period, Xenon Pharmaceuticals' Consolidated Net Income averaged around -$61.0 million, with its median value being -$57.9 million (2024).
  • Data for Xenon Pharmaceuticals' Consolidated Net Income shows a maximum YoY crashed of 12,533.71% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Xenon Pharmaceuticals' Consolidated Net Income stood at -$25.6 million in 2021, then tumbled by 46.45% to -$37.4 million in 2022, then decreased by 19.51% to -$44.7 million in 2023, then plummeted by 77.77% to -$79.5 million in 2024, then tumbled by 44.76% to -$90.9 million in 2025.
  • Its Consolidated Net Income stands at -$90.9 million for Q3 2025, versus -$84.7 million for Q2 2025 and -$65.0 million for Q1 2025.